Natera shares rise after ctDNA detection upgrade ahead of ESMO 2026
Natera shares gained about 2% after it said a refined ctDNA test boosts sensitivity, with 20 abstracts planned for ESMO 2026, per stockstory.org.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Shares of genetic testing company Natera climbed 2.4% in the afternoon session. The move followed an announcement that adding phased and structural variants lets its test detect ctDNA at levels well below one part per 10 million, improving molecular residual disease sensitivity before the ESMO 2026 Annual Congress.
The company and its partners plan to present 20 abstracts at the congress to show clinical value across its oncology portfolio. In the ICONIC trial, cancer recurrence was flagged more than 7.3 months earlier than imaging. In the SAGITTARIUS trial, 87% of colon cancer patients with negative residual disease results had their treatment plans scaled back.
After the initial jump, the stock settled at $401.75, up 2.1% from the previous close. Source: stockstory.org.
why it matters
Natera stock is already quite volatile, with 18 moves above 5% over the past year. The market seems to see this news as meaningful but not one that changes its view of the business. The shares are up 75.5% year to date and trade near their 52-week high of $425.64.
tags
instruments
sources
- Why Natera (NTRA) Stock Is Up Today — stockstory.org, 19 October 2026 at 18:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗